Anastrozole for malignant and benign conditions: present applications and future therapeutic integrations.
Anastrozole is a third-generation aromatase inhibitor with an extensive evidence base to preferentially support its use in multiple scenarios in endocrine-responsive breast cancer. These include neoadjuvant treatment, immediate and delayed adjuvant treatment, salvage treatment and first-line treatment of advanced breast cancer. Compared to tamoxifen, it offers superior efficacy and a different side effect profile that results in better tolerance and compliance. Anastrozole is considered cost effective compared with tamoxifen in a variety of healthcare systems. Anastrozole has been applied to the management of a number of endocrine conditions other than breast cancer. The major future areas of interest are in breast cancer prevention, integration with surgery, radiotherapy and other systemic targeted therapies.
Graham
Peter H
PH
Cancer Care Centre, St George Hospital, Kogarah, 2217, Australia. peter.graham@sesiahs.health.nsw.gov.au
D000077384:Anastrozole; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000517:prevention & control; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends*; D005260:Female; D006801:Humans; D009570:Nitriles / Q000494:pharmacology / Q000627:therapeutic use*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077384:Anastrozole